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1. INTRODUCTION {#jrsm1266-sec-0001}
===============

The presence of small‐study effects is a common threat to systematic reviews and meta‐analyses, especially when it is due to publication bias, which occurs when small primary studies are more likely to be reported (published) if their findings were positive.([1](#jrsm1266-bib-0001){ref-type="ref"}, [2](#jrsm1266-bib-0002){ref-type="ref"}) The presence of small‐study effects is often verified by visual inspection of the funnel plot,([3](#jrsm1266-bib-0003){ref-type="ref"}, [4](#jrsm1266-bib-0004){ref-type="ref"}, [5](#jrsm1266-bib-0005){ref-type="ref"}) where for each included study of the meta‐analysis, the estimate of the reported effect size is plotted against a measure of precision or sample size. The premise is that the scatter of plots should reflect a funnel shape, if small‐study effects do not exist (provided that effect sizes are not substantially affected by the presence of between‐study heterogeneity). However, when small studies are predominately in one direction (usually the direction of larger effect sizes), asymmetry will ensue. Because an inevitable degree of subjectivity exists in the interpretation of funnel plots, several tests have been proposed for detecting funnel plot asymmetry.([6](#jrsm1266-bib-0006){ref-type="ref"}, [7](#jrsm1266-bib-0007){ref-type="ref"}) These tests may regress effect estimates against their standard error (the so‐called Egger\'s test), their underlying sample size,[8](#jrsm1266-bib-0008){ref-type="ref"} or the inverse of their underlying sample size.[9](#jrsm1266-bib-0009){ref-type="ref"} Guidelines for conducting funnel plot asymmetry tests recommend to include at least 10 studies  to maintain sufficient power for distinguishing chance from real asymmetry.([4](#jrsm1266-bib-0004){ref-type="ref"}, [10](#jrsm1266-bib-0010){ref-type="ref"}, [11](#jrsm1266-bib-0011){ref-type="ref"})

Funnel plot asymmetry tests are currently being used for numerous types of estimates, such as odds ratios, risk ratios, and mean differences. As far as we are aware, the performance of these tests has never been evaluated for survival data,([4](#jrsm1266-bib-0004){ref-type="ref"}, [12](#jrsm1266-bib-0012){ref-type="ref"}) and it is unclear whether 10 studies are indeed sufficient to detect small‐study effects in such data.

In this paper, we investigate several approaches to evaluate small‐study effects (funnel plot asymmetry) in a meta‐analysis of hazard (rate) ratios. We propose a novel test that is tailored for survival data  and illustrate its implementation in  3 exemplar reviews. Afterwards, we compare their performance in an extensive simulation study where meta‐analyses are generated on a set of characteristics intended to reflect meta‐analyses of  randomized clinical trials in the medical literature. This simulation study adopts a new probabilistic mechanism to generate meta‐analyses that are affected by selection but do not necessarily suffer from substantial funnel plot asymmetry. In this manner, we aim to assess to what extent funnel plot asymmetry test results can be used as an indication of publication bias.

2. METHODS {#jrsm1266-sec-0002}
==========

Consider a meta‐analysis of  randomized trials, each containing a treatment and control group. Let X ~ij~ and T ~ij~ denote the allocation group (where X ~ij~=1 is treated) and uncensored survival time respectively for subjects i=1,...,n ~j~ in trial j=1,...,m. Assuming a common treatment effect across studies, let β denotes the log hazard ratio of the true treatment effect  and ${\hat{\beta}}_{j}$ the estimated treatment effect in trial j. Furthermore, let Δ~ij~ represents an indicator variable, which denotes for each subject in each study whether the event occurred during the study period (Δ~ij~=1)  or if the survival time was censored (Δ~ij~=0). The total number of events for study j is then given as $d_{j} = \sum_{i = 1}^{n_{j}}\Delta_{ij}$. Finally, we denote the censoring time points as L ~ij~, such that the observed follow‐up time for each subject is given as Z ~ij~=min(L ~ij~,T ~ij~) and the total follow‐up time for study j is given as $z_{j} = \sum_{i = 1}^{n_{j}}Z_{ij}$.

The observed data for subject i in trial j consist of \[X ~ij~,Δ~ij~,Z ~ij~\]. Subsequently, it is assumed that each trial yields a vector of study‐level data $\mathbf{S}_{j} = \lbrack{\hat{\beta}}_{j},\hat{\text{SE}}({\hat{\beta}}_{j}),n_{j},d_{j},z_{j}\rbrack$. Let $\mathbf{V} \subseteq \mathbf{S}$ now  denotes the study‐level data for m ^pb^≤m trials that are actually reported in the literature (ie, published). Below, we consider  5 methods for examining funnel plot asymmetry in published hazard ratios using information from **V**.

The most common method to test the presence of small‐study effects is given as the following (unweighted) regression model[11](#jrsm1266-bib-0011){ref-type="ref"}: $${\hat{\beta}}_{k} = a + b\;\hat{\text{SE}}({\hat{\beta}}_{k}) + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}\left( {0,\sigma^{2}} \right)$$ where k=1,...,m ^pb^ and ${\hat{\beta}}_{k}$ is the estimated log hazard ratio in study k. The unknown parameters are the intercept term a, the slope b, and the error variance σ ^2^. Whereas a indicates the size and direction of the treatment effect, b provides a measure of asymmetry; the larger its deviation from zero is, the more pronounced the asymmetry is. Otherwise, if b=0, there is no association between the estimated effect sizes ${\hat{\beta}}_{k}$ and their corresponding estimates for the standard error $\hat{\text{SE}}({\hat{\beta}}_{k})$ among the reported studies, indicating no asymmetry and thus no small‐study effects.

It is possible to allow for potential heteroscedasticity by replacing σ ^2^ with a multiplicative overdispersion parameter([7](#jrsm1266-bib-0007){ref-type="ref"}, [13](#jrsm1266-bib-0013){ref-type="ref"}) involving $\hat{var}({\hat{\beta}}_{k})$: $${\hat{\beta}}_{k} = a + b\hat{\text{SE}}({\hat{\beta}}_{k}) + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}(0,\phi\mspace{460mu}\hat{var}({\hat{\beta}}_{k}))$$

The corresponding model can be implemented by weighting the study estimates by the inverse variance of their estimated treatment effect (hence FIV, funnel inverse variance). Another method of incorporating residual heterogeneity is to include an additive between‐study variance component[14](#jrsm1266-bib-0014){ref-type="ref"}  τ ^2^.  The model is then $${\hat{\beta}}_{k} = a + b\hat{\text{SE}}({\hat{\beta}}_{k}) + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}(0,\hat{var}({\hat{\beta}}_{k}) + \tau^{2})$$ where TS stands for Thompson‐Sharp.

There are, however, several problems with using $\hat{\text{SE}}({\hat{\beta}}_{k})$ as independent (predictor) variable.([15](#jrsm1266-bib-0015){ref-type="ref"}, [16](#jrsm1266-bib-0016){ref-type="ref"}) First of all, the independent variable $\hat{\text{SE}}({\hat{\beta}}_{k})$ is estimated from the observed data and therefore prone to measurement error.[17](#jrsm1266-bib-0017){ref-type="ref"} This error becomes particularly pronounced when standard errors are derived from small samples,([18](#jrsm1266-bib-0018){ref-type="ref"}, [19](#jrsm1266-bib-0019){ref-type="ref"}, [20](#jrsm1266-bib-0020){ref-type="ref"}) thereby causing bias in estimates for the regression slope b. Additional bias may appear when there is a correlation between the measurement error and the true value of the independent variable.([8](#jrsm1266-bib-0008){ref-type="ref"}, [16](#jrsm1266-bib-0016){ref-type="ref"}) This effect has previously been discussed for funnel plot asymmetry tests involving log odds ratios,[15](#jrsm1266-bib-0015){ref-type="ref"} but may also appear when dealing with log hazard ratios. In general, aforementioned issues imply that estimates for b cannot reliably be used for hypothesis testing when $\hat{\text{SE}}({\hat{\beta}}_{k})$ is used as independent variable in the above mentioned regression models with ${\hat{\beta}}_{k}$ as outcome. For this reason, Macaskill et al  proposed using study sample size (n ~k~) as an independent variable[8](#jrsm1266-bib-0008){ref-type="ref"} $${\hat{\beta}}_{k} = a + b\; n_{k} + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}(0,\phi\mspace{460mu}\hat{var}({\hat{\beta}}_{k}))$$

Again, the intercept term a indicates the size and direction of the treatment effect, and the slope b provides a measure of asymmetry. Note that $\hat{var}({\hat{\beta}}_{k})$ is still included to allow for possible heteroscedasticity, as this strategy was found to generate favorable type‐I error rates.[8](#jrsm1266-bib-0008){ref-type="ref"} To avoid bias in estimates for b resulting from $\hat{var}({\hat{\beta}}_{k})$, Macaskill proposed an alternative test where $\hat{var}({\hat{\beta}}_{k})$ is replaced with the variance of a  pooled  estimate of the outcome proportion[8](#jrsm1266-bib-0008){ref-type="ref"}: $${\hat{\beta}}_{k} = a + b\; n_{k} + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}\left( {0,\phi\mspace{460mu}\frac{1}{d_{k}(1 - d_{k}/n_{k})}} \right)$$ where FPV stands for  funnel pooled variance.

Finally, a modification of Macaskill\'s test was proposed by Peters et al to obtain more balanced type‐I error rates in the tail probability areas.([6](#jrsm1266-bib-0006){ref-type="ref"}, [9](#jrsm1266-bib-0009){ref-type="ref"}) $${\hat{\beta}}_{k} = a + b\;\frac{1}{n_{k}} + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}\left( {0,\phi\mspace{460mu}\frac{1}{d_{k}(1 - d_{k}/n_{k})}} \right)$$

Although aforementioned tests have been evaluated for meta‐analyzing odds ratios, their application may be less appropriate for survival data where censoring influences statistical significance (and thus selective reporting) of the hazard ratio. In particular, study sample size has limited influence on the precision of estimated hazard ratios and is therefore likely to have limited power for detecting funnel plot asymmetry of reported hazard ratios. Furthermore, the study weights from the FPV methods (ie, M‐FPV and P‐FPV) are applicable to proportions and may therefore not be appropriate when some events remain unobserved  because of participant dropout.

For this reason, we propose the following regression tests that are based on the total number of events: $${\hat{\beta}}_{k} = a + b\;\frac{1}{d_{k}} + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}(0,\phi\mspace{460mu}\hat{var}({\hat{\beta}}_{k}))$$

Note that when the event rate is constant over time, $\hat{var}({\hat{\beta}}_{k})$ can be approximated[21](#jrsm1266-bib-0021){ref-type="ref"}  by $d_{k1}^{- 1} + d_{k2}^{- 1}$.  In this expression, d ~k1~ and d ~k2~ represent the number of events in the 2 compared groups (eg, treated or exposed group versus control or unexposed group) of study k. Hence, when $\hat{var}({\hat{\beta}}_{k})$ is unknown or derived from small samples, we may use $${\hat{\beta}}_{k} = a + b\;\frac{1}{d_{k}} + \epsilon_{k}\mspace{460mu},\mspace{460mu}\epsilon_{k} \sim \mathcal{N}\left( {0,\phi\mspace{460mu}\left( {\frac{1}{d_{k1}} + \frac{1}{d_{k2}}} \right)} \right)$$ where FAV stands for  funnel approximate variance.

For all methods, a 2‐tailed t‐test with test statistic $\hat{b}/\hat{\text{SE}}(\hat{b})$ and (m ^pb^−2) degrees of freedom can be performed to formally assess whether asymmetry occurs.[22](#jrsm1266-bib-0022){ref-type="ref"} Hereby, it is common to use a 10% level of significance because the number of studies in a meta‐analysis is usually low.

3. EXAMPLES {#jrsm1266-sec-0003}
===========

We illustrate the implementation of aforementioned tests for detecting funnel plot asymmetry in  3 example datasets.

3.1. Meta‐analysis of the association between plasma fibrinogen concentration and the risk of coronary heath disease {#jrsm1266-sec-0004}
--------------------------------------------------------------------------------------------------------------------

The first example dataset  composes of 31 studies in which the association between plasma fibrinogen concentration and the risk of coronary heath disease  was estimated as a log hazard ratio separately for each study.([23](#jrsm1266-bib-0023){ref-type="ref"}, [24](#jrsm1266-bib-0024){ref-type="ref"}) Across the 31 studies, the number of  coronary heath disease events ranged from 17 to 1474 and the follow‐up ranged from 4 to 33  years. Because of the low number of events, the proportion of censored events was quite high, with a median value of π ^cens^=0.96(interquartile range , 0.90 to 0.97). The corresponding funnel plots are provided in Figure [1](#jrsm1266-fig-0001){ref-type="fig"} and suggest that reported hazard ratios are larger for (small) studies with low precision. We subsequently applied the regression models presented in this article to obtain the test statistic for funnel plot asymmetry,  ie,  $\hat{b}/\text{SE}(\hat{b})$. Afterwards, we applied a 2‐tailed t‐test with 29 degrees of freedom, yielding a  P value of \<0.01(E‐UW), 0.05 (M‐FPV), 0.06 (TS), 0.07 (E‐FIV), 0.10 (D‐FIV), 0.16 (M‐FIV), and 0.18 (P‐FPV). Hence, given a nominal level of 10%, the presence of small‐study effects was (borderline) statistically significant for all tests except M‐FIV and P‐FPV.

![Funnel plots for a meta‐analysis of the association between plasma fibrinogen concentration and the risk of coronary heath disease (π ^cens^=0.96). The vertical line indicates the fixed effect estimate](JRSM-9-41-g001){#jrsm1266-fig-0001}

3.2. Meta‐analysis of the effect of erythropoiesis‐stimulating agents on overall survival {#jrsm1266-sec-0005}
-----------------------------------------------------------------------------------------

In 2009, Bohlius et al  performed an individual participant data meta‐analysis to examine the effect of erythropoiesis‐stimulating agents on overall survival in cancer patients.[25](#jrsm1266-bib-0025){ref-type="ref"} They summarized the hazard ratio of 49 randomized controlled trials that compared epoetin or darbepoetin plus red blood cell transfusions (as necessary) versus red blood cell transfusions (as necessary) alone. Also in this example, the proportion of censored events was quite high, with a median value of *π* ^cens^=0.92(interquartile range, 0.85 to 0.96). There was little evidence of between‐study heterogeneity (*I* ^2^=0*%*), and the fixed effect summary of the hazard ratio was 1.17 with a 95% confidence interval from 1.06 to 1.30. Visual inspection of the funnel plots in Figure [2](#jrsm1266-fig-0002){ref-type="fig"} did not indicate any apparent asymmetry. Aforementioned funnel plot asymmetry tests yielded a *P* value of 0.01 (M‐FIV and M‐FPV), 0.06 (P‐FPV), 0.14 (E‐FIV), 0.18 (TS), 0.30 (E‐UW), 0.50 (D‐FAV), and 0.67 (D‐FIV). In summary, with exception of the tests proposed by Macaskill and Peters, no evidence was found for the presence of small‐study effects.

![Funnel plots for a meta‐analysis of the effect of erythropoiesis‐stimulating agents on overall survival (π ^cens^=0.92). The vertical line indicates the fixed effect estimate](JRSM-9-41-g002){#jrsm1266-fig-0002}

3.3. Meta‐analysis of adjusted hazard ratios of total stroke for depressed subjects versus nondepressed subjects {#jrsm1266-sec-0006}
----------------------------------------------------------------------------------------------------------------

In 2011, Pan et al conducted a systematic review and meta‐analysis of prospective studies assessing the association between depression and risk of developing stroke in adults.[26](#jrsm1266-bib-0026){ref-type="ref"} The search yielded 28 prospective cohort studies that reported 8478 stroke cases (morbidity and mortality) during a follow‐up period ranging from 2 to 29  years. Most of the results were adjusted for age (25 studies), smoking status (20 studies), body mass index (14 studies), alcohol intake (9 studies), physical activity (7 studies), and comorbidities (23 studies; such as diabetes, hypertension, and coronary heart disease). The median proportion of censored events within studies was *π* ^cens^=0.94(interquartile range, 0.91 to 0.98). A moderate extent of heterogeneity was detected in the meta‐analysis (*I* ^2^=66*%*), and the hazard ratio from the random‐effects model was 1.45 (95*%* confidence interval, 1.29 ‐1.63). Visual inspection of the funnel plot revealed some degree of asymmetry (Figure [3](#jrsm1266-fig-0003){ref-type="fig"}), and this was confirmed by D‐FIV (*P*=0.01), E‐FIV (*P*=0.04), and TS (*P*=0.06). Conversely, the presence of small‐study effects was not supported by P‐FPV (*P*=0.11), M‐FIV (*P*=0.16), M‐FPV (*P*=0.26), and E‐UW (*P*=0.54).

![Funnel plots for a meta‐analysis of adjusted hazard ratios of total stroke for depressed subjects versus nondepressed subjects (π ^cens^=0.94). The vertical line indicates the fixed effect estimate](JRSM-9-41-g003){#jrsm1266-fig-0003}

4. SIMULATION STUDY {#jrsm1266-sec-0007}
===================

We conducted an extensive simulation study to assess the type‐I error rates and power of all aforementioned statistical tests.[27](#jrsm1266-bib-0027){ref-type="ref"} Hereto, we generated several scenarios where we varied the number of generated trials (*m*), the number of  *published*  trials (*m* ^pb^=10,20,50, or 100), the size of the true effect ( $\exp(\beta) = 1,0.75$, or 0.5), the proportion of censored events (*π* ^cens^=0*%*,30*%*, or 90*%*), and the mechanism of censoring (noninformative versus informative). All scenarios were repeated 10000 times.

4.1. Data generation {#jrsm1266-sec-0008}
--------------------

For each trial, the sample size was generated from a  log‐normal distribution with mean 6 and variance 0.6. This reflects the greater number of small trials compared to large trials as commonly observed in real meta‐analyses  and results in a mean size of $\exp(6 + 0.6/2) = 545$ subjects per trial and a standard deviation of $\sqrt{\exp(2 \times 6 + 0.6^{2}) \times (\exp\left( {0.6^{2}} \right) - 1)} = 318$. We subsequently generated a survival time for each subject in each trial according to a Weibull distribution[28](#jrsm1266-bib-0028){ref-type="ref"}: $$T_{ij} = \left( {- \frac{\log(u)}{\lambda\;\exp\left( {\beta X_{ij}} \right)}} \right)^{\frac{1}{\upsilon}}$$ with *u*∼*U*(0,1), shape parameter *υ*\>0, and a scale parameter *λ*\>0. We assumed a fixed treatment effect across trials. We set the probability of receiving a treatment in each trial to 50%,  ie, *X*∼Bernoulli(0.50), and defined β as a protective treatment effect such that $\exp(\beta) \leq 1$. Furthermore, we chose *λ*=0.03 and *v*=0.65 in accordance  with trial data from Hodgkin\'s disease.[29](#jrsm1266-bib-0029){ref-type="ref"}

4.2.  Dropout of participants {#jrsm1266-sec-0009}
-----------------------------

For each trial, we introduced  noninformative censoring to mimic random dropout of participants. Hereto, we generated censoring time points *L* ~*ij*~ from a uniform distribution *U*(0,*Q*), where *Q* was determined by iteration to yield the  prespecified censoring proportion *π* ^cens^.[30](#jrsm1266-bib-0030){ref-type="ref"} The specific value for *Q* is then dependent on the choice for *λ*, *υ*, β, and *π* ^cens^([Supporting Information](#jrsm1266-supinf-0001){ref-type="supplementary-material"}).

As an alternative scenario, we also considered informative right censoring to mimic  nonrandom dropout of trial participants. Hereto, we set the observed survival time *Z* ~*ij*~ equal to $$Z_{ij} = \left\{ \begin{matrix}
T_{ij} & {:c_{ij} = 0} \\
{L_{ij} \sim U\left( {0,T_{ij}} \right)} & {:c_{ij} = 1} \\
\end{matrix} \right.$$ with *c* ~*ij*~∼Bernoulli(*π* ^cens^).

4.3. Analysis of individual trials {#jrsm1266-sec-0010}
----------------------------------

After the introduction of participant  dropout, each trial was analyzed using Cox regression to estimate the log hazard ratio β and its corresponding standard error.

4.4. Introduction of small‐study effects {#jrsm1266-sec-0011}
----------------------------------------

For all scenarios, we varied the number of published trials by considering the following mechanisms of small‐study effects: Absence of small‐study effects. All generated trials are included in the meta‐analysis, such that *m* ^pb^=*m*.Presence of small‐study effects. A  predefined fraction of the generated trials remain unpublished, according to *m* ^pb^=*m*/1.20. To determine which trials remain unpublished, we calculated the one‐sided  *P* value (given a null hypothesis of β≥0) for each trial and subsequently sorted all trials by their  *P* value in ascending order. The rank for trial *j* is then given by *r* ~*j*~, which can be used as follows to define the probability $w_{r_{j}}$ of excluding trial *j* from the meta‐analysis ([Supporting Information](#jrsm1266-supinf-0001){ref-type="supplementary-material"}): $$w_{r_{j}} = a^{r_{j} - 1}\frac{1 - a}{1 - a^{m}}$$Because $\sum w_{r_{j}} = 1$ by definition, we can use the cumulative distribution to iteratively exclude a trial (after which we recalculate $w_{r_{j}}$ for the remaining trials) until *m* ^pb^ trials remain for meta‐analysis. We here choose *a*=1.2 to ensure that the exclusion probability for trial *r* ~*j*~ is 1.20 times higher than the exclusion probability for trial *r* ~*j*−1~, which implies that the probability of exclusion modestly increases for trials with larger *P* values. Figure S1  indicates that for *m*=11 generated trials, the study with the smallest *P* value has an exclusion probability of 3% whereas the study with the largest *P* value has an exclusion probability of 19%. When the number of generated trials increases to *m*=101, exclusion probabilities range from 2e‐7% (for *r* ~*j*~=1) to 17% (for *r* ~*j*~=101).

4.5. Evaluation of funnel plot asymmetry {#jrsm1266-sec-0012}
----------------------------------------

For all scenarios, we evaluated the presence of funnel plot asymmetry using aforementioned regression models. When applying M‐FPV, P‐FPV, D‐FIV, or D‐FPV, we added 0.5 to *d* ~*k*1~ and *d* ~*k*2~ and 2 to *n* ~*k*~ for trials with zero cell counts. We subsequently used a 2‐tailed t‐test with *m* ^pb^−2 degrees of freedom and a nominal level of 10%.

We estimated the type‐I error rate of each test by calculating the total number of  *positive*  test results in the meta‐analyses with absence (ie, no missing studies) of small‐study effects. Conversely, for meta‐analyses with presence of small‐study effects, the total number of *positive*  test results was used to estimate the power of each test.

All methods were implemented in R. The corresponding source code is available from the [Supporting Information](#jrsm1266-supinf-0001){ref-type="supplementary-material"}.

5. RESULTS {#jrsm1266-sec-0013}
==========

For the sake of simplicity, we here focus on funnel plot asymmetry tests that use the inverse variance of the estimated treatment effect as weight in the regression analysis (ie, E‐FIV, M‐FIV, and D‐FIV). We also discuss the performance of TS, as this is the only method adopting an additive heterogeneity component. The corresponding results are presented in Figure [4](#jrsm1266-fig-0004){ref-type="fig"} (type‐I error rates) and Figure [5](#jrsm1266-fig-0005){ref-type="fig"} (power) for scenarios with  noninformative dropout of participants. Results for the other tests (E‐UW, P‐FPV, M‐FPV, and D‐FAV) and for scenarios involving informative  dropout of participants are presented in the [Supporting Information](#jrsm1266-supinf-0001){ref-type="supplementary-material"}.

![Type‐I error (false positive) rates in the absence of small‐study effects. Results are presented for 3 variations of the true hazard ratio (0.5, 0.75, and 1) and for 3 variations of noninformative participant dropout within trials (values for π ^cens^ by row). Results for each scenario are based on 10 000 simulations](JRSM-9-41-g004){#jrsm1266-fig-0004}

![Power (true positive) rates in the presence of small‐study effects. Results are presented for 3 variations of the true hazard ratio (0.5, 0.75, and 1) and for 3 variations of noninformative participant dropout within trials (values for π ^cens^ by row). Results for each scenario are based on 10 000 simulations](JRSM-9-41-g005){#jrsm1266-fig-0005}

5.1. Absence of small‐study effects {#jrsm1266-sec-0014}
-----------------------------------

Results in Figure [4](#jrsm1266-fig-0004){ref-type="fig"} demonstrate that all FIV tests (E‐FIV, M‐FIV, and D‐FIV) yielded appropriate type‐I error rates (ie, around 10%) when there was no underlying effect of treatment. In scenarios where treatment efficacy was present, tests that use (estimates of) the standard error as independent predictor variable (E‐UW, E‐FIV, and TS) tended to yield excessive type‐I error rates when meta‐analyses included many studies  or when studies were affected by informative dropout (Figure S5). For instance, when the true hazard ratio was 0.50 (given *m*=100, *π* ^cens^=0.90), the type‐I error rate of E‐FIV was 12% (noninformative dropout) and, respectively, 24% (informative  dropout). Results in Figure S3  further indicate that problematic type‐I error rates also occurred for E‐UW (with estimates as high as 76%)  and, in cases of excessive  dropout, for P‐FPV and D‐FAV.  Conversely, we found that type‐I errors were below the nominal level for TS in meta‐analyses with few studies  and for D‐FIV in meta‐analyses with substantial participant  dropout.

5.2. Presence of small‐study effects {#jrsm1266-sec-0015}
------------------------------------

The power for detecting small‐study effects was relatively low for all tests, particularly when few trials were available for meta‐analysis (Figure [5](#jrsm1266-fig-0005){ref-type="fig"}). For instance, the power of D‐FIV was only 10% when $\exp(\beta) = 1.00$, *π* ^cens^=0, and *m* ^pb^=10. As anticipated, we found that the power of all tests substantially improved as more trials were included in the meta‐analysis. The highest power was achieved by E‐UW and E‐FIV (which also yielded the highest type‐I error rates). Results in  Figures  S4, S6, and S8  further indicate that M‐FIV and M‐FPV yielded low power across all situations  and that TS yielded low power when there was no underlying treatment effect ( $\exp(\beta) = 1.00$). Conversely, P‐FPV and D‐FAV performed relatively well in cases of excessive  dropout. Finally, the power of all tests was not much affected by the presence of informative  dropout ([Supporting Information](#jrsm1266-supinf-0001){ref-type="supplementary-material"}).

6. DISCUSSION {#jrsm1266-sec-0016}
=============

Small‐study effects are a major concern in systematic reviews as they may signal publication bias, such that small studies with less  favorable results are potentially missing from the meta‐analysis. For this reason, it is generally recommended to evaluate and formally test funnel plot asymmetry, provided that sufficient studies are available.([4](#jrsm1266-bib-0004){ref-type="ref"}, [10](#jrsm1266-bib-0010){ref-type="ref"}) Because most tests for evaluating small‐study effects were designed for meta‐analysis of odds ratios, we performed a simulation study to verify whether their use is also justified in survival data where hazard ratios are to be  synthesized.[21](#jrsm1266-bib-0021){ref-type="ref"} In particular, because survival data are often affected by censoring, common predictors of funnel plot asymmetry (such as total sample size) may no longer be reliable.

In line with previous findings,([7](#jrsm1266-bib-0007){ref-type="ref"}, [8](#jrsm1266-bib-0008){ref-type="ref"}, [9](#jrsm1266-bib-0009){ref-type="ref"}, [31](#jrsm1266-bib-0031){ref-type="ref"})  our results demonstrate that the performance of funnel plot asymmetry tests is rather poor. Most tests yield inadequate type‐I error rates or suffer from low power, also when applied to meta‐analysis of survival data. Although Egger\'s tests (E‐UW and E‐FIV) achieve the highest power, their type‐I error rates are too high, particularly when many studies are available for meta‐analysis or when they are affected by informative  dropout. Conversely, other existing tests with appropriate type‐I error rates tend to have poor power. This clearly casts doubt about the clinical utility of funnel plot asymmetry tests for assessing the presence of small‐study effects in meta‐analyses of survival data. We therefore developed a novel test that yields higher power than existing tests with appropriate type‐I error rates. Our novel test D‐FIV is loosely based on the test proposed by Peters  et al[22](#jrsm1266-bib-0022){ref-type="ref"} but adopts different study weights and uses the inverse of the number of events, rather than the inverse of the total sample size. Although D‐FIV and Peters\' test performed very similar in the absence of participant  dropout, D‐FIV yields more favorable type‐I error rates in the presence of censoring. For this reason, its use appears more appropriate when dealing with time‐to‐event data.

Although D‐FIV and D‐FAV are not designed for meta‐analyses with binary outcomes, they may offer an appealing choice when observed event rates are close to 1. In particular, results from the simulation study demonstrate that P‐FPV and M‐FPV become problematic when all participants experience an event (as study weights are no longer identifiable)  and that other tests suffer from low power (M‐FPV  and M‐FIV) or inappropriate type‐I error rates (E‐UW  and E‐FIV). In most situations, however, D‐FIV, D‐FAV, and P‐FPV are likely to perform similarly when participant  dropout is not an issue as the total number of events is then strongly related to the total sample size (provided that baseline risk and treatment effects do not vary much across studies).

Because it has been argued that the statistical rationale for a multiplicative variance inflation factor is rather weak,[14](#jrsm1266-bib-0014){ref-type="ref"} further improvements of D‐FIV and D‐FAV are possible by considering an additive between‐study heterogeneity component (as implemented by TS). Recent simulation studies suggest that TS‐related models perform relatively well in the presence of between‐study heterogeneity,([31](#jrsm1266-bib-0031){ref-type="ref"}, [32](#jrsm1266-bib-0032){ref-type="ref"}) but have limited power when the extent of between‐study heterogeneity is low. Our results indicate that in the absence of heterogeneity, TS essentially trades power to reduce type‐I error rates. This effect is rather problematic, as the power of most funnel plot asymmetry tests is already very low. Furthermore, the implementation of TS‐related models requires careful thought with respect to distributional assumptions and estimation methods.[15](#jrsm1266-bib-0015){ref-type="ref"}

Previously, Sterne et al  recommended 10 or more studies for testing for funnel plot asymmetry.[4](#jrsm1266-bib-0004){ref-type="ref"} However, results from our simulation study indicate that even when many (≥50) studies are available for meta‐analysis, the power for detecting the presence of small‐study effects usually remains below 50%. The performance of the presented funnel plot asymmetry tests may further deteriorate when studies are relatively small or have limited follow‐up (and continuity corrections are needed)[33](#jrsm1266-bib-0033){ref-type="ref"} or when larger studies are conducted more often in settings with small event probabilities. For this reason, it will often be necessary to explore alternative strategies to address whether reporting biases are of any concern. Suggestions for this have recently been proposed.([4](#jrsm1266-bib-0004){ref-type="ref"}, [10](#jrsm1266-bib-0010){ref-type="ref"}, [12](#jrsm1266-bib-0012){ref-type="ref"})

The methods discussed in this paper merely test for the presence of funnel plot asymmetry. Several authors have discussed the implementation of alternative methods that attempt to  *correct* meta‐analyzed estimates of treatment effect for the presence of small‐study effects.([34](#jrsm1266-bib-0034){ref-type="ref"}, [35](#jrsm1266-bib-0035){ref-type="ref"}, [36](#jrsm1266-bib-0036){ref-type="ref"}, [37](#jrsm1266-bib-0037){ref-type="ref"}) These methods make different assumptions about the mechanisms of selective reporting  and can be applied even when there is no evidence of funnel plot asymmetry. However, it has also been shown that in the strong presence of small‐study effects, regression‐based approaches may still be preferred.[38](#jrsm1266-bib-0038){ref-type="ref"} In any case, the methods presented in this paper should not be used for assessing the quality of a meta‐analysis, but rather to explore the presence of small‐study effects and to facilitate the conduct of sensitivity analyses to the potential impact of publication bias. Further, it is important to  recognize that small‐study effects may rather be caused by heterogeneity than by publication bias.[39](#jrsm1266-bib-0039){ref-type="ref"} Although we did not generate heterogeneous hazard ratios in our simulation study, recent studies have demonstrated that the performance of most funnel plot asymmetry tests deteriorates when reported effect sizes are substantially heterogeneous.([15](#jrsm1266-bib-0015){ref-type="ref"}, [32](#jrsm1266-bib-0032){ref-type="ref"})

In conclusion, when examining the presence of small‐study effects in meta‐analyses of hazard (rate) ratios, we recommend the use of our novel test D‐FIV. Our test is loosely related to Peters\' regression test but achieves better type‐I error rates when studies are affected by participant  dropout. However, because funnel plot asymmetry does not necessarily arise  because of small‐study effects, and because proper testing of funnel plot asymmetry requires access to many studies, their implementation is no panacea against selective reporting.[4](#jrsm1266-bib-0004){ref-type="ref"} Further, with few studies available for meta‐analysis, all tests have very low power for asymmetry detection of hazard ratios and thus are best avoided.
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